Introduction
Primary graft dysfunction (PGD) is a form of acute lung injury (ALI) occurring within 72 h of lung transplantation (1, 2) . It is the leading cause of early morbidity and mortality after transplant (3, 4) , yet the mechanisms driving the development of PGD remain unclear. Prior work evaluating postoperative time points has identified plasma biomarkers associated with concurrent PGD, including soluble receptor for advanced glycation end products (sRAGE), club (Clara) cell secretory protein (CC-16), Protein C and intercellular adhesion molecule-1 (ICAM-1) (5-8). These markers have helped establish potential mechanisms occurring during clinical PGD, and have demonstrated discriminant validity as a quantitative measure of PGD (9) . However, there is a lack of knowledge of mechanisms occurring prior to transplant in the recipient that may be important in the development of PGD, and better preoperative recipient risk stratification may allow for changes in management or therapy prior to transplantation to reduce the risk of PGD.
Recently, we and others have established several recipientrelated clinical risk factors for PGD, including obesity, presence of pulmonary hypertension and predisposing diagnosis (4) . Identification of the biological processes underlying these clinical PGD associations is important because it will give insight into potentially modifiable factors prior to transplantation. For example, although predisposing diagnosis is not modifiable prior to transplantation, enhanced understanding of what is driving the increased risk of a particular diagnosis may provide targets for therapy to decrease PGD risk prior to transplantation. Additionally, studying biological markers within known risk groups is important as there are likely several different mechanisms contributing to the risk of PGD and measurement of biomarkers may allow for individualized management decisions to decrease PGD risk.
In order to further study potential mechanisms underlying previously established clinical risk factors and identify potential biological targets prior to transplantation to reduce the risk of development of PGD, we tested the association between five known PGD lung injury biomarkers measured preoperatively in the recipient and the subsequent risk of development of PGD.
Methods

Study population
The Lung Transplant Outcomes Group cohort is a multi-center, prospective study that has been previously described (5, 6) . In prior studies, we have measured postoperative biomarkers in smaller subsets of this cohort study (6) (7) (8) . In this study, we measured five preoperative biomarkers in a large cohort of subjects that is expanded and distinct from previously studied cohorts. We included subjects transplanted between July 2002 and May 2010 with at least one biomarker measurement at the preoperative time point. The majority of samples were collected immediately prior to transplantation during the transplant admission; however, a fraction was collected at the time of listing. Samples were processed within 60 min and then stored at À808C for subsequent analysis, and clinical data were collected prospectively for all subjects as described previously (5, 7, 10) . Mortality information was collected from each center and supplemented with data from United Network for Organ Sharing (11) . Institutional Review Board approval was obtained from each participating center. Informed consent was obtained from each subject enrolled in the cohort.
Determination of PGD grade
Our primary outcome was Grade 3 PGD at 48 or 72 h after transplantation. PGD grade was determined using the International Society for Heart and Lung Transplantation consensus definition (2, 10, 12) . Two blinded physicians examined chest radiographs to assess for the presence of PGD. Radiographs qualified for PGD if the transplanted lung(s) had diffuse infiltrates. Radiographs and arterial blood gases were assessed at the time of admission to the ICU after transplantation (T0), and 24, 48 and 72 h after transplantation. The severity of PGD was graded according to the PaO 2 /FiO 2 ratio, with a PaO 2 /FiO 2 ratio less than 200 defining Grade 3 PGD (13).
Measurement of sRAGE, ICAM-1, Protein C, IL-8 and CC-16
Biomarkers were chosen because of previously reported associations with ALI or PGD (5, 7, 14, 15) . Protein C was measured using the Actichrome Protein C assay (American Diagnostica, Greenwich, CT). The intra-assay coefficient of variation was 5.5%. sRAGE, ICAM-1 and IL-8 were measured by ELISA (R&D, Minneapolis, MN). The intra-assay coefficients of variation were 7%, 5% and 3%, respectively. CC-16 levels were measured using a commercially available ELISA (Biovender, Candler, NC). The intra-assay coefficient of variation was 4%. All analytes were measured in duplicate.
Statistical analysis
Biomarkers were analyzed either continuously or using quartiles, based on fractional polynomial fit plots evaluating the relationship between each biomarker and predicted probabilities of PGD (16) , as well as categorizing each biomarker into quartiles as a dummy variable in logistic regression models with PGD as the outcome. We evaluated CC-16 stratified by diagnosis (idiopathic pulmonary fibrosis [IPF] vs. non-IPF) based on our previous finding that diagnosis is an effect modifier of the relationship between CC-16 and PGD (8, 17) . We performed a sensitivity analysis of the association of biomarkers by time of collection, repeating the analyses in those subjects who had plasma collected at the time of listing, defined as greater than 24 h prior to transplantation.
We used multivariable logistic regression to evaluate the relationship between each biomarker and PGD while evaluating for confounding using variables previously demonstrated to be risk factors for PGD, including BMI, mean pulmonary arterial pressure (mPAP), transplant type, ischemic time, FiO 2 at reperfusion, female sex and parity, pretransplant diagnosis, donor smoking (defined as any history of smoking) and use of cardiopulmonary bypass (18) . Using a prediction model previously developed (19) for PGD using bootstrap resampling methods, which incorporated pretransplant diagnosis, obesity and pulmonary artery pressure, we evaluated significant biomarkers for incremental predictive utility by comparing area under the curve (AUC) for the model with an individual biomarker to the model without. A likelihood ratio test was used to evaluate for significant differences in AUC. Multiple imputation was used to account for missing data in the covariates (20) . Imputation was not used in either the exposure (biomarker) or the outcome (grade of PGD) variables; the very few individuals with missing biomarker values were excluded from analyses. p-Values of less than 0.05 were considered significant. Analyses were performed using STATA version 12.0 (STATA Corp., College Station, TX).
Results
There were 714 subjects in the study, of which 130 (18%, 95% CI: 15%, 21%) developed PGD. The majority of plasma samples were obtained at the time of transplantation; however, there were 126 subjects (19%) who had samples collected more than 24 h prior to transplantation. In those subjects, plasma samples were collected at the time of listing. The average time between collection and transplantation in those subjects was 80 AE 96 days. Missing biomarker values (n ¼ 2) were due to assay failure.
Subjects with PGD more frequently received a lung from a smoking donor, were more obese and had IPF and PAH more often as a pretransplant diagnosis (10) . Additionally, subjects with PGD had higher mPAP, more frequent red blood cell transfusions and more frequent use of cardiopulmonary bypass ( Table 1 ). The percentage of missing data for each covariate is listed in Table 1 . There were no significant differences in plasma levels of sRAGE, ICAM-1, IL-8 and Protein C between those with PGD and those without ( Table 2) .
Median plasma CC-16 levels were higher in subjects with PGD compared to those without (10. and pretransplant diagnosis (stratified as IPF vs. non-IPF), we found that the highest quartile of CC-16 had more subjects with IPF compared to other diagnoses (118 vs. 60, p < 0.001). There was no detectable association between CC-16 and PGD in subjects with IPF (OR for highest quartile of CC-16 1.38, 95% CI: 0.43, 4.45, p ¼ 0.59). Plasma CC-16 levels were higher in subjects with PGD than without in the sub-group of non-IPF subjects (Figure 2A and B Given the association between preoperative plasma CC-16 and PGD, we evaluated CC-16 as a possible predictor for PGD in non-IPF subjects. First, we evaluated the predictive utility of CC-16 alone, which had an AUC of 0.60. Then, based on a previous study (19) , we analyzed the predictive utility of pretransplant diagnosis, BMI category and mPAP as a base model. The negative predictive value of this model was 93%, and the positive predictive value was 20%. With the addition of CC-16 to the model, there were no significant improvements in the negative or positive predictive values (90% and 15%, respectively), despite statistically significant improvement in the AUC (0.72 for model with CC-16 vs. 0.70 for base clinical model, p ¼ 0.04). Therefore, although elevated preoperative plasma CC-16 is an independent risk factor and possible biomarker of PGD, it may not be clinically useful in prediction of PGD when added to known clinical predictor variables.
In sensitivity analyses, the relationship between the biomarkers and the PGD did not change significantly by time of sample collection. In subjects who had samples collected at the time of transplantation, the relationship between CC-16 and PGD was unchanged (OR for highest quartile of CC-16: 2.07, 95% CI: 1.00, 4.31, p ¼ 0.05). In subjects who had samples collected greater than 24 h from the time of transplantation (n ¼ 174), there was no change in the relationship between CC-16 and PGD (OR for the highest quartile of CC-16 was 3.8, 95% CI: 1.19, 12.14, p ¼ 0.02). There were not enough subjects to perform a stratified analysis by individual diagnosis category.
Discussion
In this study, we have demonstrated an association between plasma CC-16 levels measured preoperatively and PGD. This association was the strongest in subjects without IPF as a pretransplant diagnosis, and in subjects in the highest quartile of plasma CC-16. The association was independent of adjustment from multiple known confounding variables, indicating that the level of epithelial injury, as represented by circulating CC-16 levels, may predispose to PGD prior to the transplant procedure. Although CC-16 was not a good predictor of PGD, we have demonstrated the utility of CC-16 as a preoperative marker of PGD. This study builds on our prior work evaluating biomarkers in PGD (5, 6, 8) by exclusively evaluating the preoperative time point in a large cohort of prospectively studied transplant recipients, with adequate power to evaluate the role of biomarkers in prespecified sub-groups. CC-16 is secreted by epithelial cells in the distal respiratory tract and acts to protect the integrity of the epithelial lining against inflammation and oxidant stress (21) . In sarcoidosis, CC-16 is a biomarker of parenchymal disease severity, with increased levels being reflective of increasing parenchymal disease (15, 22) . CC-16 has also been evaluated as a biomarker of ALI, and plasma levels measured at the time of injury are decreased compared to other causes of pulmonary edema (23, 24) . In our study, increased plasma levels of CC-16 in the recipient prior to transplantation are associated with subsequent PGD. The difference in directionality from ALI may be because our measurement was taken prior to the development of lung injury, not during, indicating that preexisting epithelial injury is associated with subsequent graft dysfunction. It is possible that systemic up-regulation of lung epithelial injury pathways prior to transplantation leads to an increased susceptibility of PGD. Future investigation on the systemic immune effectors of these pathways in the posttransplant period is important.
We found that the association was the strongest in subjects without IPF as a pretransplant diagnosis. Overall, subjects with IPF had a significantly higher CC-16 level compared to other pretransplant diagnoses. The lack of association between CC-16 and PGD in IPF subjects may be that subjects with IPF already had such a strong signal of epithelial injury prior to transplantation that any subsequent injury related to PGD is difficult to detect as levels in IPF patients are so high (25) . Alternatively, a recent study demonstrated that chronic obstructive pulmonary disease (COPD) patients with high levels of circulating inflammatory markers in a symptom-free period had a greater number of exacerbations (26) . It may be that patients with COPD and other non-IPF diagnoses with high CC-16 levels are a subgroup of ''exacerbators'' that are at increased risk for (3) 3 (2) 15 (3) Pulmonary arterial hypertension (4) 13 (10) 15 ( When added to a predictive model using clinical covariates, CC-16 only had a slight increase in utility for predicting PGD.
Our findings indicate that preoperative CC-16 levels are independently associated with PGD, and worthy of further study into the mechanism of development of PGD in those subjects without IPF, although it has not been proven a useful predictor of those who will go on to develop PGD when measured preoperatively.
We were unable to demonstrate an association between Protein C, ICAM-1, lL-8 and sRAGE at the preoperative time point and PGD. Protein C, ICAM-1 and sRAGE have established associations with PGD at postoperative time point (5,7) and IL-8 is a marker of ALI (27) ; IL-8 was recently demonstrated to have good predictive utility for ALI when measured in the emergency department. Our inability to detect an association between these biomarkers and the subsequent development of PGD may be because these biomarkers reflect mechanisms that are activated by the process of ischemia-reperfusion injury, and not mechanisms that are active in the recipient prior to transplantation. Additionally, a small proportion of our preoperative biomarkers was measured at months prior to transplantation, and may have diluted our ability to detect an association using these biomarkers.
Our study has several limitations. First, not all of the plasma measurements were taken at the same time point, so there may have been other confounding factors associated with the earlier measurements. However, in sensitivity analyses, the association between CC-16 and PGD was unchanged in subjects who had plasma measurements at the time of listing or at the time of transplantation. This increases applicability of our findings, as the association was still present with biomarkers measured early; it supports the hypothesis that there may be time for potential interventions prior to transplantation. Second, we do not have available data on concomitant immunosuppressant medications at the time of preoperative blood draws. Although prior studies have successfully measured these markers in the setting of concomitant steroid use, little is known about the effect of immunosuppressants on human plasma levels; thus, residual confounding may account for some of our negative results (23, (28) (29) (30) . Third, we used multiple imputation to account for missing data in the covariates; however, missing data on clinical covariates were rare and we had no missing PGD grade and minimal missing biomarker measurements within the cohort.
In conclusion, we have demonstrated an association between preoperative levels of CC-16 and PGD in subjects without IPF as a pretransplant diagnosis. This finding sheds light on pretransplant, potentially modifiable factors that may lead to PGD. Further research is warranted focusing on the mechanisms of how recipient epithelial injury ''primes'' the lung for subsequent PGD. 
